How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Document

    Please indicate which stakeholder group listed most closely represents you:
    1. Industry (manufacturer of medicines, health technologies or equipment)
    2. Trade body / association
    3. Consultancy
    4. University / academic
    5. Government department
    6. Other public sector organisation
    7. Voluntary and community sector organisation
    8. Health or social care practitioner
    9. Member of the public
    10. Other (provide detail)

  • Question on Document

    Have we considered all the relevant evidence in preparation for adopting the EQ-5D-5L value set? Is our interpretation of the evidence appropriate?

  • Question on Document

    Are the changes to the NICE technology appraisal and highly specialised technologies guidance manual (PMG36) appropriate?

  • Question on Document

    Are the changes to the developing NICE guidelines manual (PMG20) appropriate?

  • Question on Document

    Is it clear when alternative methods for capturing health-related quality of life may be accepted, and what the preferred hierarchy is for selecting from the available alternatives?

  • Question on Document

    Beyond what is described in the equality and health inequality impact assessment, are there any aspects of the proposed changes that need particular consideration to ensure they do not result in unlawful discrimination against any group of people on the grounds of age, disability, gender reassignment, pregnancy and maternity, race, religion or belief, sex or sexual orientation?

  • Question on Document

    If you have any further comments in relation to the proposed changes set out in this consultation, please include them here.

Modular update to NICE manuals EQ-5D-5L value set: Evidence review document

Open for comments Open until   Request commenting lead permission

We have updated this service so that members of the same organisation can now collaborate on a joint online response.

Read our blog to learn more.

5 Proposed changes to the NICE manuals

5.1

Based on the evidence, our recommendation is that the NICE technology appraisal and highly specialised technologies guidance manual (PMG36) and the developing NICE guidelines manual (PMG20) require updating to stipulate that utility values in reference-case analyses should be calculated using the EQ-5D-5L descriptive system and the UK value set published by Rowen et al. (2026). It will state that data gathered using the EQ-5D-3L descriptive system should be mapped onto the 5L value set, using the mapping function and dataset recommended in the current manual (PMG36). Appendix A has details on the proposed amendments to the manuals' wording.

5.2

The EQ-5D-5L descriptive system and value set should also be used for any HealthTech evaluations that require cost–utility analyses. However, the NICE HealthTech programme manual (PMG48) does not require any updates because it does not mention the EQ-5D measure and directs stakeholders to the technology appraisal and highly specialised technologies guidance manual (PMG36) for information on measuring and valuing health effects in cost–utility analyses.

5.3

In line with NICE's modular updates framework, available as part of a public board paper (Word), the updated methods will be prospectively applied to NICE guidance. That is, for all topics for which the evaluation started after the publication date of the updated manuals. For technology appraisals and highly specialised technologies (HST) guidance this refers to the invitation to participate, and for HealthTech evaluations this refers to the topic launch. For NICE guidelines this refers to topic selection.

5.4

Existing NICE recommendations using the EQ-5D-3L value set will not be reviewed solely to incorporate the EQ-5D-5L value set. Guidance will be updated only if there are changes to the evidence base, clinical pathway or economic case that are likely to have a material effect on the recommendations.